Systematic review of treatments for recurrent abdominal pain

ABSTRACT. Objective. To conduct a systematic re-view of evaluated treatments for recurrent abdominal pain (RAP) in children. Methods. Online bibliographic databases were searched for the terms “recurrent abdominal pain,” “functional abdominal pain, ” “children, ” or “alternative therapies ” in articles classified as randomized controlled trials. The abstracts or full text of 57 relevant articles were examined; 10 of these met inclusion criteria. Inclusion criteria required that the study involve children aged 5 to 18 years, subjects have a diagnosis of RAP, and that subjects were allocated randomly to treatment or control groups. The methodology and findings of these articles were evaluated critically, and data were extracted from each article regarding study methods, specific interven-tions, outcomes measured, and results. Results. Studies that evaluated famotidine, pizotifen, cognitive-behavioral therapy, biofeedback, and pepper-mint oil enteric-coated capsules showed a decrease in measured pain outcomes for those who received the in-terventions when compared with others in control groups. The studies that evaluated dietary interventions had conflicting results, in the case of fiber, or showed no efficacy, in the case of lactose avoidance. Conclusions. Evidence for efficacy of treatment of RAP in children was found for therapies that used famo-tidine, pizotifen, cognitive-behavioral therapy, biofeed-back, and peppermint oil enteric-coated capsules. The effects of dietary fiber were less conclusive, and the use of a lactose-free diet showed no improvement. There seemed to be greater improvement when therapy (famo-tidine, pizotifen, peppermint oil) was targeted to the specific functional gastrointestinal disorder (dyspepsia, abdominal migraine, irritable bowel syndrome). The be-havioral interventions seemed to have a general positive effect on children with nonspecific RAP. Many of these therapies have not been used widely as standard treat-ment for children with RAP. Although the mechanism of action for each effective therapy is not fully understood, each is believed to be safe for use in RAP. Pediatrics 2003;111:e1–e11